Skip to content
← All treatment topics

TREATMENT READING

Childhood Myeloid Proliferations Associated With Down Syndrome

Source sections for this topic, with the original link and date. Patient and professional reading are labelled separately.

Not medical advice · Not a complete treatment or trial directory

Made by Triangle.

Selected text from the National Cancer Institute, with the original link and date. Made by Triangle. This page is not an NCI PDQ summary. Source topics may be broader than an individual diagnosis.

Health professional

Special Considerations for the Treatment of Children With Cancer

Source: Childhood Myeloid Proliferations Associated With Down Syndrome Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: September 16, 2024. Captured 2026-09-09.

Cancer in children and adolescents is rare, although the overall incidence has slowly increased since 1975.[1] Children and adolescents with cancer should be referred to medical centers that have a multidisciplinary team of cancer specialists with experience treating the cancers that occur during childhood and adolescence.[2] This multidisciplinary team approach incorporates the skills of the following pediatric specialists and others to ensure that children receive treatment, supportive care, and rehabilitation to achieve optimal survival and quality of life:

Sources: 1 · 2

Primary care physicians.

Pediatric surgeons.

Pathologists.

Pediatric radiation oncologists.

Pediatric medical oncologists and hematologists.

Rehabilitation specialists.

Pediatric oncology nurses.

Social workers.

Child-life professionals.

Psychologists.

Nutritionists.

For specific information about supportive care for children and adolescents with cancer, see the summaries on Supportive and Palliative Care.

Sources: Supportive and Palliative Care

The American Academy of Pediatrics has outlined guidelines for pediatric cancer centers and their role in the treatment of children and adolescents with cancer.[3] At these centers, clinical trials are available for most types of cancer that occur in children and adolescents, and the opportunity to participate is offered to most patients and their families. Clinical trials for children and adolescents diagnosed with cancer are generally designed to compare potentially better therapy with current standard therapy. Other types of clinical trials test novel therapies when there is no standard therapy for a cancer diagnosis. Most of the progress in identifying curative therapies for childhood cancers has been achieved through clinical trials. Information about ongoing clinical trials is available from the NCI website.

Sources: 3 · NCI website

This page is made by Triangle. The reading above is selected source text, not a treatment recommendation, and it is not medical advice.

Health professional · Transient Abnormal Myelopoiesis (TAM) Associated With Down Syndrome

Treatment of TAM

Source: Childhood Myeloid Proliferations Associated With Down Syndrome Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: September 16, 2024. Captured 2026-09-09.

While observation is appropriate for most infants with TAM, therapeutic intervention is warranted in patients with apparent severe hydrops or organ failure. Because TAM eventually spontaneously remits, treatment is short in duration and primarily aimed at the reduction of leukemic burden and resolution of immediate symptoms. Several treatment approaches have been used, including the following:

Exchange transfusion.

Leukapheresis.

Low-dose cytarabine. Of these approaches, only cytarabine has been shown to consistently reduce TAM complications and related mortality.[3,6]; [14][Level of evidence B4] Cytarabine dosing has ranged from 0.4 to 1.5 mg/kg per dose given intravenously (IV) or subcutaneously (SC) once to twice daily for 4 to 12 days.[6] This dosing schedule has produced similar efficacies and less toxicity than higher doses given in continuous 5-day infusions, which led to prolonged severe neutropenia.[3] A prospective trial examined the use of low-dose cytarabine (1.5 mg/kg per day IV or SC for 7 days) to treat symptomatic patients. This trial reported a significant reduction in early death using this regimen, compared with similar patients in the historical control group (12% ± 5% vs. 33% ± 7%, respectively; P = .02).[14][Level of evidence B4]

Sources: 3 · 6 · 14 · Level of evidence B4 · 6 · 3 · 14 · Level of evidence B4

Health professional · Myeloid Leukemia of Down Syndrome (MLDS)

Treatment of Newly Diagnosed Childhood MLDS

Source: Childhood Myeloid Proliferations Associated With Down Syndrome Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: September 16, 2024. Captured 2026-09-09.

Appropriate therapy for younger children (aged ≤4 years) with MLDS is less intensive than current standard childhood AML therapy. Hematopoietic stem cell transplant is not indicated in first remission.[4,9-14,18,19]

Sources: 4 · 9 · 14 · 18 · 19

Treatment options for newly diagnosed children with MLDS include the following:

Chemotherapy.

Evidence (chemotherapy):

In a Children's Oncology Group (COG) trial for newly diagnosed children with MLDS (AAML0431 [NCT00369317]), 204 children received a regimen that substituted high-dose cytarabine for the second of four induction cycles (thereby reducing cumulative anthracycline exposure from 320 mg to 240 mg), moving this cycle from intensification where it was used in the previous COG A2971 (NCT00003593) trial.[10,11] Intrathecal doses were reduced from seven to two total injections, and intensification included two cycles of cytarabine/etoposide.

Sources: AAML0431 [NCT00369317] · A2971 (NCT00003593) · 10 · 11

In a Children's Oncology Group (COG) trial for newly diagnosed children with MLDS (AAML0431 [NCT00369317]), 204 children received a regimen that substituted high-dose cytarabine for the second of four induction cycles (thereby reducing cumulative anthracycline exposure from 320 mg to 240 mg), moving this cycle from intensification where it was used in the previous COG A2971 (NCT00003593) trial.[10,11] Intrathecal doses were reduced from seven to two total injections, and intensification included two cycles of cytarabine/etoposide.

When compared with the previous trial, these changes resulted in an overall improvement of approximately 10%.

The EFS rate was 89.9%, and the OS rate was 93%.

Relapse occurred in 14 patients and there were two treatment-related deaths, both related to pneumonia, neither of which occurred during induction 2.

No patient had central nervous system (CNS) involvement in this trial or the preceding COG A2971 trial.[10]

Sources: 10

The only prognostic factor identified was MRD using flow cytometry on day 28 of induction 1. Among those who were MRD negative (≤0.01%), the disease-free survival (DFS) rate was 92.7%. In the 14.4% of patients who were MRD positive, the DFS rate was 76.2% (P = .011).

In the COG AAML1531 (NCT00369317) trial for children with newly diagnosed MLDS, removing the high-dose cytarabine cycle in those with standard-risk MLDS was unsuccessful.[16]

Sources: AAML1531 (NCT00369317) · 16

In the COG AAML1531 (NCT00369317) trial for children with newly diagnosed MLDS, removing the high-dose cytarabine cycle in those with standard-risk MLDS was unsuccessful.[16]

The interim analysis found that patients who did not receive high-dose cytarabine had a lower 2-year EFS rate of 85.6%, compared with the 2-year EFS rate of 93.5% for patients in the AAML0431 trial (P = .0002).

In a joint trial (ML-DS 2006) from the BFM, Dutch Childhood Oncology Group (DCOG), and Nordic Society of Pediatric Hematology and Oncology (NOPHO), 170 children with Down syndrome were enrolled. This trial focused on reducing therapy by eliminating etoposide during consolidation, reducing the number of intrathecal doses from 11 to 4, and the elimination of maintenance from the reduced-therapy Down syndrome arm of AML-BFM 98.[13] As in the COG trials, no patient had CNS disease at diagnosis. The following two prognostic factors were identified:[13]

Sources: 13 · 13

In a joint trial (ML-DS 2006) from the BFM, Dutch Childhood Oncology Group (DCOG), and Nordic Society of Pediatric Hematology and Oncology (NOPHO), 170 children with Down syndrome were enrolled. This trial focused on reducing therapy by eliminating etoposide during consolidation, reducing the number of intrathecal doses from 11 to 4, and the elimination of maintenance from the reduced-therapy Down syndrome arm of AML-BFM 98.[13] As in the COG trials, no patient had CNS disease at diagnosis. The following two prognostic factors were identified:[13]

Outcomes were no worse despite reduction in chemotherapy. The OS rate was 89% (± 3%), and the EFS rate was 87% (± 3%), similar to that observed in AML-BFM 98 (OS rate, 90% ± 4% [P = NS]; EFS rate, 89% ± 4% [P = NS]). The CIR rate was 6% in both trials.

Nine patients relapsed, and seven of those patients died.

Patients with a good early response (<5% blasts by morphology before induction cycle 2, n = 123 [72%]) had better outcomes (OS rate, 92% ± 3% vs. 57% ± 16%, P < .0001; EFS rate, 88% ± 3% vs. 58% ± 16%, P = .0008; and CIR rate, 3% ± 2% vs. 27% ± 18%, P = .003).

Less toxicity was seen in this trial, and treatment-related mortality remained low (2.9% vs. 5%, P = .276).

Trisomy 8 was an adverse factor (n = 37; OS rate, 77% vs. 95%, P = .07; EFS rate, 73% ± 8% vs. 91% ± 4%, P = .018; CIR rate, 16% ± 7% vs. 3% ± 2%, P = .02).

This was confirmed in multivariate analysis, where lack of good early response and trisomy 8 maintained their adverse impact on relapse, with relative risks of 8.55 (95% confidence interval [CI], 1.96–37.29; P = .004) and 4.36 (95% CI, 1.24–15.39; P = .022), respectively.

A 2024 analysis included a cohort of Japanese patients with MLDS (n = 204) who were treated with uniform chemotherapy. Patients underwent extensive somatic testing to further define variants most commonly seen with this diagnosis. Somatic variants in 26 genes known to be driver genes in MLDS were identified again. These included variants in cohesin and cohesin-related proteins (43.6%), epigenetic regulators (39.2%), tyrosine kinases (25.5%), and genes important in the RAS pathway (11.8%). An additional 16 novel genes were also described. Of these, variants in two transcription factors (IRX1: 16.2%; ZBTB7A: 13.2%) were found, and functional studies confirmed their role as tumor suppressor genes that impacted signaling through MYC/E2F pathways. Structural variants were also observed. RUNX1 partial tandem duplications were seen in 13.7% of patients, which may result in partial loss of function of the gene. This causes upregulation expression through the addition of an extra promoter, which results in isoform disequilibrium, with RUNX1A bias versus RUNX1. Recent studies have shown that this disequilibrium contributes to MLDS pathogenesis. Variants of RUNX1, IRX1, and ZBTB7A also activate MYC/E2F genes, suggesting that targeting this pathway may provide therapeutic benefit.[20]

Sources: 20

A 2024 analysis included a cohort of Japanese patients with MLDS (n = 204) who were treated with uniform chemotherapy. Patients underwent extensive somatic testing to further define variants most commonly seen with this diagnosis. Somatic variants in 26 genes known to be driver genes in MLDS were identified again. These included variants in cohesin and cohesin-related proteins (43.6%), epigenetic regulators (39.2%), tyrosine kinases (25.5%), and genes important in the RAS pathway (11.8%). An additional 16 novel genes were also described. Of these, variants in two transcription factors (IRX1: 16.2%; ZBTB7A: 13.2%) were found, and functional studies confirmed their role as tumor suppressor genes that impacted signaling through MYC/E2F pathways. Structural variants were also observed. RUNX1 partial tandem duplications were seen in 13.7% of patients, which may result in partial loss of function of the gene. This causes upregulation expression through the addition of an extra promoter, which results in isoform disequilibrium, with RUNX1A bias versus RUNX1. Recent studies have shown that this disequilibrium contributes to MLDS pathogenesis. Variants of RUNX1, IRX1, and ZBTB7A also activate MYC/E2F genes, suggesting that targeting this pathway may provide therapeutic benefit.[20]

Four somatic alterations were associated with inferior outcomes in this study cohort.

A 2024 analysis included a cohort of Japanese patients with MLDS (n = 204) who were treated with uniform chemotherapy. Patients underwent extensive somatic testing to further define variants most commonly seen with this diagnosis. Somatic variants in 26 genes known to be driver genes in MLDS were identified again. These included variants in cohesin and cohesin-related proteins (43.6%), epigenetic regulators (39.2%), tyrosine kinases (25.5%), and genes important in the RAS pathway (11.8%). An additional 16 novel genes were also described. Of these, variants in two transcription factors (IRX1: 16.2%; ZBTB7A: 13.2%) were found, and functional studies confirmed their role as tumor suppressor genes that impacted signaling through MYC/E2F pathways. Structural variants were also observed. RUNX1 partial tandem duplications were seen in 13.7% of patients, which may result in partial loss of function of the gene. This causes upregulation expression through the addition of an extra promoter, which results in isoform disequilibrium, with RUNX1A bias versus RUNX1. Recent studies have shown that this disequilibrium contributes to MLDS pathogenesis. Variants of RUNX1, IRX1, and ZBTB7A also activate MYC/E2F genes, suggesting that targeting this pathway may provide therapeutic benefit.[20] › Four somatic alterations were associated with inferior outcomes in this study cohort.

Of 177 patients with comprehensive somatic testing, CDKN2A deletions and variants in ZBTB7A, TP53, and JAK2 were all associated with inferior outcomes.

If patients had at least one of these variants, EFS and OS rates were significantly lower than those of patients who lacked any four of these abnormalities (3-year EFS rates, 66.6% vs. 94.2%; P for unadjusted Cox regression < .001; 3-year OS rates, 69.0% vs. 95.6%; P for unadjusted Cox regression < .001).

In multivariable analysis, all of these abnormalities were associated with inferior outcomes.

Validation of these findings in additional cohorts is needed. However, these findings may help identify patients with higher-risk MLDS in the future.

Children with mosaicism for trisomy 21 are treated similarly to those children with clinically evident Down syndrome.[8,10,21] Children with MLDS who are older than 4 years have a significantly worse prognosis.[14] Although an optimal treatment for these children has not been defined, they are usually treated with AML regimens designed for children without Down syndrome.

Sources: 8 · 10 · 21 · 14

Health professional · Myeloid Leukemia of Down Syndrome (MLDS) / Treatment of Newly Diagnosed Childhood MLDS

Treatment options under clinical evaluation

Source: Childhood Myeloid Proliferations Associated With Down Syndrome Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: September 16, 2024. Captured 2026-09-09.

Information about National Cancer Institute (NCI)–supported clinical trials can be found on the NCI website. For information about clinical trials sponsored by other organizations, see the ClinicalTrials.gov website.

Sources: NCI website · ClinicalTrials.gov website

Health professional · Myeloid Leukemia of Down Syndrome (MLDS)

Treatment of Relapsed or Refractory Childhood MLDS

Source: Childhood Myeloid Proliferations Associated With Down Syndrome Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: September 16, 2024. Captured 2026-09-09.

A small number of trials address outcomes in children with MLDS who relapse after initial therapy or who have refractory MLDS. In three prospective trials of children with newly diagnosed MLDS, outcomes were poor for those who relapsed (4 of 11, 2 of 9, and 2 of 12 patients who relapsed survived).[9,13,16] Thus, these children are treated similarly to children without Down syndrome, with an intensive reinduction chemotherapy regimen. If a remission is achieved, therapy is followed by an allogeneic hematopoietic stem cell transplant (HSCT).

Sources: 9 · 13 · 16

Treatment options for children with refractory or relapsed MLDS include the following:

Chemotherapy, which may be followed by an allogeneic HSCT.

Evidence (treatment of children with refractory or relapsed MLDS):

Four analyses have specifically examined children with relapsed or refractory MLDS.[22-25]

Sources: 22 · 25

The Japanese Pediatric Leukemia/Lymphoma Study Group reported the outcomes of 29 patients with relapsed (n = 26) or refractory (n = 3) MLDS. As expected with Down syndrome, the children in this cohort were very young (median age, 2 years); relapses were almost all early (median, 8.6 months; 80% <12 months from diagnosis); and 89% had M7 French-American-British classification.[22][Level of evidence C1]

Sources: 22 · Level of evidence C1

The Japanese Pediatric Leukemia/Lymphoma Study Group reported the outcomes of 29 patients with relapsed (n = 26) or refractory (n = 3) MLDS. As expected with Down syndrome, the children in this cohort were very young (median age, 2 years); relapses were almost all early (median, 8.6 months; 80% <12 months from diagnosis); and 89% had M7 French-American-British classification.[22][Level of evidence C1]

In contrast to the excellent outcomes achieved after initial therapy, only 50% of the children attained a second remission, and the 3-year OS rate was 26%. Attainment of second remission was more successful the later the relapse occurred after completing initial therapies.

Approximately one-half of the children underwent allogeneic transplant, and no advantage was noted for transplant compared with chemotherapy. However, the number of patients was small.

A Center for International Blood and Marrow Transplant Research study of children with MLDS who underwent allogeneic HSCT reported the following results:[23][Level of evidence C1]

Sources: 23 · Level of evidence C1

A Center for International Blood and Marrow Transplant Research study of children with MLDS who underwent allogeneic HSCT reported the following results:[23][Level of evidence C1]

A similarly poor outcome, with a 3-year OS rate of 19%.

The main cause of failure after transplant was relapse, which exceeded 60%. Survival was significantly worse for patients who relapsed early.

The transplant-related mortality was approximately 20%.

A Japanese registry study reported better survival after transplant of children with MLDS using reduced-intensity conditioning regimens compared with myeloablative approaches. However, the number of patients was very small (n = 5), and the efficacy of reduced-intensity approaches in children with MLDS requires further study.[24][Level of evidence C2]

Sources: 24 · Level of evidence C2

The largest study to date was conducted by a consortium of pediatric cooperative groups and select North American institutions. The study retrospectively evaluated children with MLDS to determine their outcomes and prognostic factors for survival after relapse or refractory disease.[25]

Sources: 25

The largest study to date was conducted by a consortium of pediatric cooperative groups and select North American institutions. The study retrospectively evaluated children with MLDS to determine their outcomes and prognostic factors for survival after relapse or refractory disease.[25]

The most common site of relapse was bone marrow (61 of 62 patients), and no CNS relapses were reported.

Median time to relapse was 6.8 months, and 82% of relapses occurred within 12 months of initial diagnosis.

Time to relapse, use of HSCT, and attainment of second complete remission (CR) before transplant were prognostically significant.

For the entire cohort, the OS rate was 22.1%, the EFS rate was 20.9%, and the cumulative relapse rate was 79.1%.

The median time from relapse or refractory disease to time of death was 5.1 months (0.4–41 months).

The 3-year OS rate was 46% for those who achieved remission (45% of patients).

HSCT was performed in 29 patients. Undergoing HSCT in second CR was critically important, with 6 of 19 patients relapsing after HSCT if initially in second CR, compared with 9 of 10 patients relapsing if they went to transplant when not in second CR. Among the 29 HSCT recipients, the 3-year OS rate was 39.8%, and the EFS rate was 36.7%.

Only 3 of 33 patients who received chemotherapy alone ultimately survived (3-year OS and EFS rates, 6.4%).

For patients

Treatment of Transient Abnormal Myelopoiesis or Children with Down Syndrome and AML

Source: Childhood Acute Myeloid Leukemia/Other Myeloid Malignancies Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: June 5, 2024. Captured 2026-09-09.

For information about the treatments listed below, see the Treatment Option Overview section.

Sources: Treatment Option Overview

Transient abnormal myelopoiesis (TAM) usually goes away on its own. For newly diagnosed TAM that does not go away on its own or causes other health problems, treatment may include the following:

Sources: Transient abnormal myelopoiesis · diagnosed

Supportive care, including transfusion therapy or leukapheresis.

Sources: Supportive care · transfusion · leukapheresis

Chemotherapy.

Sources: Chemotherapy

Treatment of newly diagnosed acute myeloid leukemia (AML) in children aged 4 years or younger who have Down syndrome may include the following:

Sources: acute myeloid leukemia · Down syndrome

Combination chemotherapy plus central nervous system prophylaxis therapy with intrathecal chemotherapy.

Sources: Combination chemotherapy · central nervous system prophylaxis · intrathecal chemotherapy

A clinical trial of a new chemotherapy regimen that depends on how the child responds to initial chemotherapy.

Sources: clinical trial · regimen · responds

Treatment of newly diagnosed AML in children older than 4 years who have Down syndrome may be the same as treatment for children without Down syndrome.

Studies

Chemotherapy in Treating Children With Down Syndrome and Myeloproliferative Disorder, Acute Myelogenous Leukemia, or Myelodysplastic Syndrome

NCT00003593 · COMPLETED · phase3

Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms

ClinicalTrials.gov record

Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes

NCT00369317 · COMPLETED · phase3

Childhood Acute Basophilic Leukemia, Childhood Acute Eosinophilic Leukemia, Childhood Acute Erythroleukemia (M6), Childhood Acute Megakaryocytic Leukemia (M7), Childhood Acute...

ClinicalTrials.gov record

Disease and treatment settings

Childhood Myeloid Proliferations Associated With Down Syndrome

Disease and treatment setting

Myeloid Proliferations Associated With Down Syndrome in children and adolescents

Childhood Myeloid Proliferations Associated With Down Syndrome

Disease and treatment setting

Treatment of Newly Diagnosed Childhood MLDS

refractory Childhood Myeloid Proliferations Associated With Down Syndrome

Disease and treatment setting

Treatment of Relapsed or Refractory Childhood MLDS